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COMMENTARY
The management of type 2 diabetes before, 
during and after Covid-19 infection: what 
is the evidence?
Leszek Czupryniak1*, Dror Dicker2,3†, Roger Lehmann4†, Martin Prázný5† and Guntram Schernthaner6,7*  
Abstract 
Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of 
whether glucose-lowering therapy should be adjusted during infection and how to manage a return to normal 
care after resolution of Covid-19 symptoms. Due to the sudden onset of the pandemic, physicians have by neces-
sity made such important clinical decisions in the absence of robust evidence or consistent guidelines. The risk to 
patients is compounded by the prevalence of cardiovascular disease in this population, which alongside diabetes is 
a major risk factor for severe disease and mortality in Covid-19. We convened as experts from the Central and Eastern 
European region to consider what advice we can provide in the setting of type 2 diabetes and Covid-19, considering 
the evidence before, during and after infection. We review recommendations that have been published to date, and 
consider the best available—but currently limited—evidence from large observational studies and the DARE-19 ran-
domized control trial. Notably, we find a lack of guidance on restarting patients on optimal antidiabetic therapy after 
recovering from Covid-19, and suggest that this may provide an opportunity to optimize treatment and counter clini-
cal inertia that predates the pandemic. Furthermore, we emphasize that optimization applies not only to glycaemic 
control, but other factors such as cardiorenal protection. While we look forward to the emergence of new evidence 
that we hope will address these gaps, in the interim we provide a perspective, based on our collective clinical experi-
ence, on how best to manage glucose-lowering therapy as patients with Covid-19 recover from their disease and 
return to normal care.
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Introduction
Physicians are adapting to a new era in healthcare 
brought about by the Covid-19 pandemic.[1] Among the 
myriad of challenges faced is the management of patients 
for whom Covid-19 risk is elevated, especially given the 
epidemiological evidence that diabetes and cardiovascu-
lar disease are major risk factors for severe Covid-19 and 
mortality.[2]–[13].
As experts in diabetology from the Central and Eastern 
European region, we convened to consider what advice 
we can provide for clinicians managing patients with type 
2 diabetes, including the large proportion of patients who 
also present with cardiovascular disease or high cardio-
vascular risk. We note that several recommendations are 
already published, albeit with some contradictions;[14]–
[21] however, we do not feel there are sufficient data avail-
able for us to adjudicate between these recommendations 
or to make our own evidence-based recommendations. 
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Furthermore, we are concerned about the lack of guid-
ance on restarting patients on optimal antidiabetic ther-
apy post-Covid-19, and the potential impact of clinical 
inertia with regards to optimizing glucose-lowering ther-
apy.[22].
As the pandemic progresses, we expect more evidence 
to emerge that may help to inform diabetes management 
in a Covid-19 setting. A first step comes from a real-
world report on Covid-19 mortality among patients with 
type 2 diabetes in the UK. This nationwide study sug-
gested that the pandemic does not provide grounds to 
change overall glucose-lowering drug preferences.[23].
In this article, we summarize what is and what is not 
known about managing type 2 diabetes during the Covid-
19 pandemic, discuss recommendations made to date, 
review the implications of the latest real-world evidence, 
and make our own suggestions for patients who are 
returning to normal care after recovery from Covid-19.
Why does diabetes care need updating for the Covid‑19 
era?
In patients with diabetes, the rates of severe disease and 
mortality during Covid-19 infection are elevated com-
pared with non-diabetic individuals.[2]–[12, 23] Several 
pathological mechanisms have been proposed to under-
lie this phenomenon, and have been detailed extensively 
elsewhere [24]–[31]. Hyperglycemia is also associated 
with mortality [32, 33], raising the possibility that long-
term optimal glucose control in the general diabetes 
population may be of particular importance for reduc-
ing mortality risk for those patients who later contract 
Covid-19.
Epidemiological studies have identified factors other 
than hyperglycaemia that heighten risk among patients 
with diabetes who are infected with Covid-19; unsur-
prisingly, these include advanced age and systemic 
inflammation as well as comorbidities such as obesity, 
hypertension, coronary artery disease, chronic kidney 
disease, and a history of stroke or heart failure [1, 6, 10, 
33]–[49]. The widespread prevalence of these comor-
bidities, and proposed pathological overlap between 
their pro-inflammatory and pro-coagulative states and 
Covid-19, has added new complexity to diabetes care 
[10, 24, 25, 35, 40, 50]–[56], as has the observation that 
in some patients inflammation may be ongoing after 
the resolution of acute Covid-19 [57]. Similarly, even 
after discharge, the risk of mortality or new onset major 
adverse cardiovascular events (MACE) may remain high 
[10]. Elderly patients with type 2 diabetes may be a par-
ticular concern, owing to the position of advanced age as 
the most significant risk factor for poor outcomes with 
Covid-19.
The challenge of managing diabetes [1, 58] and its 
comorbidities [59] while under pandemic (and, at times, 
lockdown) conditions adds to the burden placed upon 
physicians. Of particular concern, there may be more 
restricted access to new initiation of glucose-lowering 
drugs; [60] meanwhile, patients’ control of diabetes may 
worsen [61]. Covid-19 itself has been linked to fluctuat-
ing and elevated glucose levels that can be indicative of 
poor prognosis, and can be difficult to manage upon hos-
pitalization [33, 47, 48, 62]–[65].
Inadequate glycaemic control can be a risk factor for 
the development of diabetic ketoacidosis (DKA), [66]–
[68] which is typically seen in patients who are volume-
depleted as a result of fever and inadequate fluid intake, 
[66] symptoms that can occur in Covid-19. By contrast, 
little is known about hypoglycaemia in patients with 
Covid-19; in non-Covid-19 settings, hypoglycaemia can 
be a significant risk factor for poor outcomes in intensive 
care [69].
In the case of the glucagon-like peptide-1 receptor 
agonist (GLP-1 RA) and sodium–glucose transporter 2 
inhibitor (SGLT2i) classes, patients may miss out on the 
important cardiorenal benefits that these agents offer 
[22, 60]—attributes that may even warrant exploration 
for the treatment mild or moderate Covid-19. Access to 
cardiology services themselves may also be impeded. In 
the first wave of the pandemic, several studies reported 
reductions in acute cardiovascular hospitalizations that 
suggested delayed care, such as primary percutaneous 
coronary intervention (PCI) procedures in patients with 
diabetes and ST-segment elevation myocardial infarc-
tion (STEMI) [70]–[73]. Even after admission, testing for 
Covid-19 status can delay necessary treatment [74]. An 
international study also found a stark reduction in diag-
nostic procedures [75]. Collectively, estimates have sug-
gested that the impact on cardiology services will lead 
to a large number of excess deaths as an indirect conse-
quence of Covid-19.[76] It is hoped that access has sub-
sequently improved, but some issues may still remain and 
could re-emerge in the event of new waves of large-scale 
hospitalizations.
Beyond diabetes and its immediate comorbidities, the 
overall physical and mental health of patients with dia-
betes can also decline due to the socioeconomic impacts 
of Covid-19, such as lockdown, economic hardship and 
bereavement; indeed, anxiety has increased in patients 
with diabetes [1]. Thus, some patients with type 2 diabe-
tes are particularly vulnerable during the pandemic.
What evidence and recommendations are available 
for glycaemic control in a Covid‑19 setting?
Following a literature search, we have reviewed various 
recommendations [14]–[21] and reviews [77, 78] now 
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available on managing diabetes in a Covid-19 setting 
(Table  1). While we applaud the efforts to rapidly dis-
seminate advice in the fast-evolving circumstances of a 
novel virus pandemic, the challenge for physicians is that 
the guidance in some aspects lacks consistency (Fig. 1a) 
[14]–[21]. This is largely because of the many data gaps 
that mean we still cannot say definitively whether each 
glucose-lowering drug class has a negative, positive or 
neutral effect on Covid-19 outcomes. In particular, we 
find that there is minimal guidance on how to restart glu-
cose-lowering therapies after temporary cessation due to 
Covid-19 [14]–[21, 77, 78]. 
There is also only limited, if any, guidance on how to 
de-intensify insulin regimens after discharge in patients 
initiated with insulin during hospitalization [14]–[21, 77, 
78]—a scenario that has become more common due to 
the frequent need for insulin in patients hospitalized with 
Covid-19. For these patients, we can apply our existing 
knowledge from discharging patients in non-Covid-19 
settings, as the principles are similar; the challenge is 
only to ensure that expertise on best practice is shared 
with the greater number of clinicians who may now be 
managing patients in such a scenario.
Overall, evidence is conflicting as to which glucose-
lowering drugs are associated with the most favourable 
outcomes in patients with Covid-19 (Fig.  1b) and for 
the most part relies on observational data rather than 
randomized controlled trials. Large mortality studies 
have suggested either a benefit or no significant differ-
ence with metformin [23, 79]–[87] and SGLT2i; [39, 
65]–[88] a benefit or neutral effect or even a negative 
effect with dipeptidyl peptidase-4 inhibitors (DPP-4i); 
[23, 89]–[101] a benefit or neutral effect with GLP-1 
RA; [23, 88, 95] and a negative effect with insulin 
(Table  2) [23, 63, 102]–[104]. However, these obser-
vations may well be largely explained by confounders, 
and it is still not clear whether any of glucose-lower-
ing agents provide true protection from Covid-19 [23, 
88, 105]. Despite our reservations, the data do provide 




















































Fig. 1 Recommendations and evidence for different classes of glucose-lowering drugs in patients with type 2 diabetes in a Covid-19 setting. A 
Recommendations for the management of type 2 diabetes in a Covid-19 setting have consistently advocated for the use of insulin (not shown) 
in patients hospitalized with severe Covid-19, but are less consistent in guidance for other glucose-lowering drug classes. Shown in this panel is 
the maximum severity of Covid-19 where various publications have recommended that metformin, SGLT2i, GLP-1 RA or DPP-4i can be continued 
in patients with type 2 diabetes. B Several large real-world studies have sought to compare mortality and other serious outcomes among 
glucose-lowering drugs in patients with Covid-19; however, these studies are limited by significantly different patient profiles between cohorts 
that may lead to confounding, even with the best efforts to control for biases. To avoid confounders, randomized controlled trials are need. One 
such study, DARE-19, has recently shown a trend towards positive outcomes with SGLT2i that was considered hypothesis generating, but was not 
statistically significant
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insulin where confounding factors were considered the 
likely explanation for the apparent negative effect [23].
For SGLT2i, a recent randomized controlled trial 
provided further reassurance on safety. In the DARE-
19 study, 1,250 patients hospitalized with Covid-19 at 
95 sites in the US, Brazil, Mexico, Argentina, India, 
Canada and the UK, and who had cardiometabolic 
risk factors for developing serious complications, were 
randomized to receive dapagliflozin (an SGLT2i) or 
placebo between April 2020 and January 2021 [106]. 
Around half the patients had type 2 diabetes, and none 
had type 1 diabetes [106]. After 30 days, 11% of patients 
assigned to dapagliflozin and 14% of patients assigned 
to placebo had either died or suffered organ failure, 
most commonly respiratory or cardiovascular decom-
pensation; looking at mortality only, the rates were 7% 
with dapagliflozin and 9% with placebo [106]. Although 
there was no statistically significant improvement in 
these outcomes, as had been hoped for, the investiga-
tors noted the trends favouring dapagliflozin, with 
numerically lower rates, and on that basis considered 
the results to be hypothesis generating [106].
As other endpoints were similar between the two 
groups, and overall adverse events were fewer with 
dapagliflozin than placebo, the DARE-19 study was 
at least able to demonstrate that the use of SGLT2i in 
patients hospitalized with Covid-19 is well tolerated 
and does not seem to elevate the risk for poor outcomes 
[106]. We would find it of interest to see further ran-
domized controlled trials of SGLT2i, as well as GLP-1 
RA, perhaps restricted to patients with mild-to-moder-
ate Covid-19, with a view to preventing progression to 
severe disease or death.
Recommendations for managing glucose-lowering 
therapy have sought to discriminate between patients 
at risk of—but not infected with—Covid-19; patients 
who have mild disease that does not require hospitali-
zation; patients who are hospitalized but not in critical 
care; and patients who are critically ill [14]–[21]. Based 
on these criteria, recommendations published to date 
have tended to agree on favouring insulin in hospital-
ized patients, where management of hyperglycaemia 
upon admission is a concern [14]–[21]. However, out-
side an intensive care setting, safe insulin dosing and 
glucose monitoring protocols are used inconsistently or 
not at all, which may result in increased risk of hypo-
glycaemia [107]. Safer treatments that could be consid-
ered include fixed-ratio formulations of GLP-1 RA or 
SGLT2i with basal insulin [107].
Some recommendations also note that DPP-4i can be 
considered in addition to insulin in the hospital setting, 
which may be highly relevant given the overlap in the 
elderly profile of DPP-4i recipients and patients hospi-
talized with Covid-19 [23].
Where recommendations disagree is on how to apply 
sick day rules for SGLT2i and metformin during Covid-
19 infection, with some advocating for sick day rules with 
any degree of illness and others reserving this for hospi-
talized or even critically ill patients [14]–[21]. There is 
more agreement that no change to normal glucose-low-
ering treatment is needed in patients who may be at risk 
of infection but who are not currently infected.
If patients requiring hospitalization for Covid-19 con-
tinue on SGLT2i, they should be monitored for DKA, 
which can occur in patients with Covid-19 independently 
of treatment, but can sometimes also be associated with 
SGLT2i use [66]–[68, 108]–[116]. For patients with 
Covid-19 who are not hospitalized, we suggest that fac-
tors that may increase the risk for DKA are considered, 
namely fluid loss due to diarrhoea or low intake of food 
and drink due to a suppressed appetite or gastrointesti-
nal symptoms. Patients on metformin with hypoxaemia 
or organ failure should be monitored for the risk of lactic 
acidosis, which can occur under these conditions [81].
Due to the paucity of data, all recommendations are 
based on clinical judgement alone, and made out of 
necessity without extensive, robust evidence. For this 
reason, and until such data are available, recommenda-
tions should be treated with caution and considered to be 
heavily caveated.
We are also mindful that the harm of suboptimal man-
agement of diabetes should not be overlooked, especially 
as inadequate glycaemic control has been linked to poor 
outcomes in patients with Covid-19 [52, 62]–[64]. Simi-
larly, losing the cardiorenal protective effects and weight 
loss benefits of SGLT2i [117] and GLP-1 RA [22] may 
be detrimental given the cardiorenal risk posed by both 
type 2 diabetes and Covid-19, a question that remains 
open after the inconclusive results of the DARE-19 study 
[106]. Finally, while data on hypoglycaemia in patients 
with Covid-19 are limited, this should not deter clinicians 
from preferring therapies with a low risk of these events.
Taking together our clinical experience and the review 
of literature discussed here, we suggest that the basic 
principles of glucose-lowering therapy for patients with 
type 2 diabetes in a Covid-19 setting could be directed as 
outlined in Fig. 2.
After Covid‑19: how can we make sure that patients return 
to optimal control of type 2 diabetes?
Given that sick day rules and other recommendations 
may lead to treatment discontinuations in a Covid-19 
setting, patients are at risk of losing the benefits of an 
optimized glucose-lowering drug regimen, especially if 
there is no systematic process for restarting treatment. 
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However, for patients who had not previously been on 
a regimen optimized to the latest guidelines, treatment 
interruption or modification due to Covid-19 could 
also provide an opportunity to optimize glucose-lower-
ing therapy upon recovery.
For those patients who do need to temporarily 
change their glucose-lowering regimen, the question 
remains as to when to de-intensify insulin and optimize 
treatment following recovery from Covid-19. More 
guidance is urgently needed to answer this question, 
but once again we are currently hampered by a lack of 
evidence.
Unfortunately, it is not straightforward to determine 
whether a patient has recovered from Covid-19; even 
once the infection has cleared, other sequalae may remain 
for some time, and risk of re-admission, MACE and even 
mortality remain high for a period; [118] it is not known 
whether this is a consideration for restarting glucose-
lowering drugs. These difficulties are compounded by the 
overall strain placed on diabetes and cardiology services 
during the pandemic [1, 75] and the lack of guidance 
on post-Covid-19 care, with recommendations instead 
focusing on patients who are infected or at risk of infec-
tion [14]–[21]. The lack of guidance is of particular con-
cern when bearing in mind that management of patients 
who are recovering from Covid-19 may be carried out, in 
most countries, by non-diabetes specialists.
Unless these challenges are overcome, patients may 
lose the benefit of their usual treatment regimen, opti-
mized for well-controlled glycaemia and safety consid-
erations; discontinuation may worsen glycaemic control 
and/or increase the likelihood of adverse effects such as 
hypoglycaemia. Furthermore, many patients with type 
2 diabetes also have co-morbidities that would benefit 
from the various cardiorenal protective effects offered by 
agents within the SGLT2i and GLP-1 RA classes. Drug 
prescription data both prior to [22, 119, 120] and during 
[23] the Covid-19 pandemic has shown that many eligible 
patients do not receive SGLT2i or GLP-1 RA.
While any guidance should be received with caution, 
given the paucity of data, from our clinical experience 
and according to our literature review we would suggest 
that the basic principles of discharge could be directed as 
follows. Briefly, we advise that de-intensification should 
be considered at the time of discharge in patients with 
an intensified insulin regimen, taking into account effi-
cacy, safety, patient burden, patient comfort and patient 
satisfaction with insulin treatment. The decision should 
be based on shared, informed decision-making with both 








• Insulin (if needed)
As per latest diabetes 
guidelines
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severe COVID-19 disease (ICU)
Recommended (2nd line)
*No longer widely used in some countries
Fig. 2 Suggested principles of glucose-lowering therapy for type 2 diabetes in a Covid-19 setting. In light of the limited available data, including 
observational studies and the DARE-19 trial, together with diabetes guidelines developed prior to the pandemic, we cautiously suggest these 
principles of glucose-lowering therapy in a Covid-19 setting. We emphasize that these suggestions are based on our clinical opinion and are not 
evidence-based, due to the paucity of evidence
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and nephrologists, with whom specific comorbidities and 
special needs should be discussed, such as the benefits 
of medication offering cardiorenal protection, weight 
reduction or low risk of hypoglycaemia. The decision 
could thereby be perceived as an opportunity to improve 
patient outcomes beyond Covid-19, with optimized anti-
hyperglycaemic treatment as per modern guidelines.
If it is decided that insulin should not be de-intensified 
at discharge, a timeline of 1 and/or 3 months should be 
set for re-assessment, which could involve telemedicine 
options such as online visits, telephone contact or remote 
access to data from glucose monitoring systems. Fre-
quent monitoring and insulin down-titration are advised 
if the patient continues with a corticosteroid for Covid-
19 following discharge from hospital.
Conclusions
The sudden onset of the Covid-19 pandemic has forced 
diabetologists to make clinical decisions without the 
level of evidence that would normally be expected. As 
time progresses, some studies are beginning to shed 
light on the potential impact of various glucose-lowering 
drugs on outcomes such as mortality. However, these are 
mostly observational studies, while the DARE-19 trial 
had relatively modest patient numbers and inconclusive 
results. Notwithstanding these caveats, the emerging evi-
dence suggests that no particular class of glucose-lower-
ing drug carries an elevated risk; outside of an intensive 
setting, patients may be best served by continuing on 
their current regimens, with monitoring for DKA or lac-
tic acidosis where appropriate.
While the danger posed by Covid-19 may be receding, 
the risks of poor glycaemic control and cardiorenal dis-
ease remain ever present [22]. Therefore, our hope is that 
management of type 2 diabetes during the pandemic will 
lead to new opportunities to optimize treatment to pro-
long life for patients and improve its quality.
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